RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
CY Biotech of Taiwan has acquired greater China rights to lorcaserin, an anti-obesity treatment from Japan’s Eisai (TYO: 4523). CYB already distributes lorcaserin in Taiwan under a separate agreement with Eisai, which owns Asian rights to the drug. CYB will make an upfront payment plus milestones upon regulatory approval. Further details were not disclosed. CYB aims to offer innovative products to the self-paid market in a wide range of indications, The company has a China subsidiary, Chuang Yi Trading Limited, based in Shanghai.
Source: China Biotoday
